Skip to content

Study · Randomized controlled trial · n = 73 · 2010

3 results

The effect of thymosin treatment of venous ulcers.

Guarnera G, DeRosa A, Camerini R

Annals of the New York Academy of Sciences1 Apr 2010Cited by 20 (Europe PMC)

PMID20536470 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05490.x (opens in a new tab)PepBankPUB-20536470
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with venous stasis ulcers, the safety profile of all topical Tbeta4 doses was acceptable and comparable to placebo.

    In plain wordsIn people with venous ulcers, thymosin beta‑4 applied to the skin at all doses had a safety profile comparable to placebo.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeSafety profile of topical Tbeta4
    Study

    n = 73

    Comparator
    Placebo
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    all doses (dose-escalation) · topicalAs given in this study (human).

    Source sentences

    Summary
    The safety profile of all doses of administered Tbeta4 was deemed acceptable and comparable to placebo.
    1 context sentence
    Summary · context
    To assess the safety, tolerability, and efficacy of topically administered Tbeta4 in patients with venous stasis ulcers, a double-blind, placebo-controlled, dose-escalation study was conducted in eight European sites (five in Italy and three in Poland) that enrolled and randomized 73 patients.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with venous stasis ulcers, phase 2 efficacy findings suggest that a Tbeta4 dose of 0.03% may have the potential to accelerate wound healing.

    In plain wordsIn people with venous ulcers, a 0.03% thymosin beta‑4 dose may have the potential to speed up wound healing.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAccelerated wound healing at 0.03% dose
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    0.03% · topicalAs given in this study (human).

    Source sentences

    Summary
    Efficacy findings from this Phase 2 study suggest that a Tbeta4 dose of 0.03% may have the potential to accelerate wound healing and that complete wound healing can be achieved within 3 months in about 25% of the patients, especially among those whose wounds are small to moderate in size or mild to…
    1 context sentence
    Summary · context
    To assess the safety, tolerability, and efficacy of topically administered Tbeta4 in patients with venous stasis ulcers, a double-blind, placebo-controlled, dose-escalation study was conducted in eight European sites (five in Italy and three in Poland) that enrolled and randomized 73 patients.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In a phase 2 trial in patients with venous stasis ulcers, complete wound healing within 3 months was achievable in about 25% of patients, especially those with small to moderate wounds or mild to moderate severity.

    In plain wordsIn a phase 2 trial in people with venous ulcers, about 25% could have complete healing within 3 months, especially with smaller wounds.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableComplete wound healing within 3 months
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · topicalAs given in this study (human).

    Measurements

    Complete healing within 3 months
    ≈ 25%
    patients

    Source sentences

    Summary
    Efficacy findings from this Phase 2 study suggest that a Tbeta4 dose of 0.03% may have the potential to accelerate wound healing and that complete wound healing can be achieved within 3 months in about 25% of the patients, especially among those whose wounds are small to moderate in size or mild to…
    1 context sentence
    Summary · context
    To assess the safety, tolerability, and efficacy of topically administered Tbeta4 in patients with venous stasis ulcers, a double-blind, placebo-controlled, dose-escalation study was conducted in eight European sites (five in Italy and three in Poland) that enrolled and randomized 73 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.